Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study.
Mao YY, Cai HC, Shen KN, Chang L, Zhang L, Zhang Y, Feng J, Wang W, Yang C, Zhu TN, Duan MH, Zhou DB, Cao XX, Li J.
Mao YY, et al. Among authors: zhang l, zhang y.
Ann Hematol. 2022 Apr;101(4):831-836. doi: 10.1007/s00277-022-04764-4. Epub 2022 Jan 17.
Ann Hematol. 2022.
PMID: 35039900
Clinical Trial.